KCNMA1 Knockout cell line (PC-3)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

KCNMA1 (potassium calcium-activated channel subfamily M alpha 1) encodes the alpha subunit of the large-conductance calcium-activated potassium (BK) channel. This channel integrates intracellular calcium signals with membrane potential to regulate ion flux and cellular excitability. KCNMA1 contributes to physiological processes including smooth muscle contraction, neurotransmitter release, and neuronal excitability. Mutations in KCNMA1 are associated with several neurological disorders, including paroxysmal nonkinesigenic dyskinesia, idiopathic generalized epilepsy, and Liang-Wang syndrome.

PC-3 is a human prostate cancer cell line established from a bone marrow metastasis of a poorly differentiated grade IV prostatic adenocarcinoma from a 62-year-old male patient after androgen suppression therapy. The cells are androgen-independent, exhibit low acid phosphatase and testosterone-5-alpha reductase activity, and are capable of growing in soft agar and forming tumors in nude mice. PC-3 is widely used as a model for studying advanced prostate cancer biology, androgen-independent tumor progression, metastasis, and anticancer drug development.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.